Experts discuss the benefits of implementing and operationalizing bispecifics in the community oncology setting.
Video content above is prompted by the following:
What are the benefits of implementing/operationalizing bispecifics in the community oncology setting?
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More